BioNxt Solutions Inc. (CSE:BNXT)
Canada · Delayed Price · Currency is CAD 0.2600
-0.0250 (-8.77%)
Oct 30, 2026, 9:46 AM EDT
BioNxt Solutions Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
35.38M
Revenue by Geography
- Germany 16.35K 60.6%
- Austria 6.22K 23.1%
- Switzerland 4.41K 16.3%
Fiscal year ended Dec 31, 2024 See the full BioNxt Solutions breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 197.59M |
| Planet 13 Holdings | 131.28M |
| Vext Science | 71.97M |
| Rubicon Organics | 64.23M |
| Leef Brands | 47.36M |
| LSL Pharma Group | 41.83M |
| MediPharm Labs | 41.46M |
| Medicure | 32.08M |
BioNxt Solutions News
- 11 days ago - BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate - Accesswire
- 7 weeks ago - BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study - Accesswire
- 2 months ago - BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies - Accesswire
- 2 months ago - BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants - Accesswire
- 2 months ago - BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies - Accesswire
- 2 months ago - BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline - Accesswire
- 3 months ago - BioNxt Solutions Announces Option Grants - Accesswire
- 3 months ago - BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway - Accesswire